166 related articles for article (PubMed ID: 25332032)
41. The National Health Service Bowel Cancer Screening Program: the early years.
Rees CJ; Bevan R
Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5):421-37. PubMed ID: 23899282
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of family history-based colorectal cancer screening in Australia.
Ouakrim DA; Boussioutas A; Lockett T; Hopper JL; Jenkins MA
BMC Cancer; 2014 Apr; 14():261. PubMed ID: 24735237
[TBL] [Abstract][Full Text] [Related]
43. Impact of bowel cancer screening on the management of colorectal cancer.
Hwang MJ; Evans T; Lawrence G; Karandikar S
Colorectal Dis; 2014 Jun; 16(6):450-8. PubMed ID: 24617851
[TBL] [Abstract][Full Text] [Related]
44. Beliefs about bowel cancer among the target group for the National Bowel Cancer Screening Program in Australia.
Jalleh G; Donovan RJ; Lin C; Slevin T; Clayforth C; Pratt IS; Ledger M
Aust N Z J Public Health; 2010 Apr; 34(2):187-92. PubMed ID: 23331364
[TBL] [Abstract][Full Text] [Related]
45. Cost-utility analysis of colonoscopy or faecal immunochemical test for population-based organised colorectal cancer screening.
Areia M; Fuccio L; Hassan C; Dekker E; Dias-Pereira A; Dinis-Ribeiro M
United European Gastroenterol J; 2019 Feb; 7(1):105-113. PubMed ID: 30788122
[TBL] [Abstract][Full Text] [Related]
46. Characteristics of patients aged 50–74 years with a request for an immunochemical faecal occult blood test in the Australian general practice setting.
Pollack A; Busingye D; Thistlethwaite J; Blogg S; Chidwick K
Aust Health Rev; 2022 Apr; 46(2):222-232. PubMed ID: 35220996
[TBL] [Abstract][Full Text] [Related]
47. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
[TBL] [Abstract][Full Text] [Related]
48. Australia's national bowel cancer screening program: does it work for indigenous Australians?
Christou A; Katzenellenbogen JM; Thompson SC
BMC Public Health; 2010 Jun; 10():373. PubMed ID: 20579344
[TBL] [Abstract][Full Text] [Related]
49. Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme.
Lee TJ; Rutter MD; Blanks RG; Moss SM; Goddard AF; Chilton A; Nickerson C; McNally RJ; Patnick J; Rees CJ
Gut; 2012 Jul; 61(7):1050-7. PubMed ID: 21940723
[TBL] [Abstract][Full Text] [Related]
50. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
Mandel JS; Church TR; Ederer F; Bond JH
J Natl Cancer Inst; 1999 Mar; 91(5):434-7. PubMed ID: 10070942
[TBL] [Abstract][Full Text] [Related]
51. Impact of a mass media campaign on participation in the Australian bowel cancer screening program.
Durkin S; Broun K; Guerin N; Morley B; Wakefield M
J Med Screen; 2020 Mar; 27(1):18-24. PubMed ID: 31530160
[TBL] [Abstract][Full Text] [Related]
52. Prevalence of FOB testing in eastern-Australian general practice patients: what has a national bowel cancer screening program delivered?
Paul CL; Carey ML; Russell G; D'Este C; Sanson-Fisher RW; Zwar N
Health Promot J Austr; 2015 Apr; 26(1):39-44. PubMed ID: 25818504
[TBL] [Abstract][Full Text] [Related]
53. General practice perspectives on a bowel cancer screening quality improvement intervention using the Consolidated Framework for Implementation Research.
Holden CA; Turnbull D; Frank OR; Olver I
Public Health Res Pract; 2021 Sep; 31(3):. PubMed ID: 34494074
[TBL] [Abstract][Full Text] [Related]
54. Colorectal cancer screening in rural and remote areas: analysis of the National Bowel Cancer Screening Program data for South Australia.
Martini A; Javanparast S; Ward PR; Baratiny G; Gill T; Cole S; Tsourtos G; Aylward P; Jiwa M; Misan G; Wilson C; Young GP
Rural Remote Health; 2011; 11(2):1648. PubMed ID: 21585228
[TBL] [Abstract][Full Text] [Related]
55. The impact of personalised risk information compared to a positive/negative result on informed choice and intention to undergo colonoscopy following colorectal Cancer screening in Scotland (PERICCS) - a randomised controlled trial: study protocol.
Steele RJC; Digby J; Chambers JA; O'Carroll RE
BMC Public Health; 2019 Apr; 19(1):411. PubMed ID: 30991987
[TBL] [Abstract][Full Text] [Related]
56. Return to bowel screening after a false-positive faecal immunochemical test in BowelScreen (the National Bowel Screening Programme in Ireland).
Ch'ng BX; Mooney T; O'Donoghue D; Fitzpatrick P
J Med Screen; 2019 Dec; 26(4):186-190. PubMed ID: 31345130
[No Abstract] [Full Text] [Related]
57. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
58. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program.
Cole SR; Tucker GR; Osborne JM; Byrne SE; Bampton PA; Fraser RJ; Young GP
Med J Aust; 2013 Apr; 198(6):327-30. PubMed ID: 23545032
[TBL] [Abstract][Full Text] [Related]
59. Colon capsule endoscopy in colorectal cancer screening: a randomised controlled trial.
Kaalby L; Deding U; Kobaek-Larsen M; Havshoi AV; Zimmermann-Nielsen E; Thygesen MK; Kroeijer R; Bjørsum-Meyer T; Baatrup G
BMJ Open Gastroenterol; 2020 Jun; 7(1):. PubMed ID: 32601101
[TBL] [Abstract][Full Text] [Related]
60. Screening for colorectal cancer using the fecal occult blood test: an actuarial assessment of the impact of a population-based screening program in Canada.
Villeneuve PJ; Coombs A
Int J Technol Assess Health Care; 2003; 19(4):715-23. PubMed ID: 15095779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
